505(b)(2) Program: BTG’s Paxclitaxel Gel for Oesophageal Cancer
- Posted by: Ken Phelps
- Published on: April 17, 2009
Media is reporting that BTG’s Phase IIa study of a novel gel formulation of paxclitaxel showed tumor reduction in 70% of patients. In effect, BTG is taking a known agent and directly targeting the affected tissues; BTG is also reportedly in later phase trials looking at this gel product in brain cancer – placing the gel directly in the brain cavity after surgery.